Skip to main content
SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD logo

SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002737 ISIN · CNE100001WT7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,262 across all filing types
Latest filing 2024-10-28 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002737

About SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD

https://www.kuihuayaoye.com

Sunflower Pharmaceutical Group Co., Ltd. focuses on the research, development, manufacturing, and distribution of proprietary Chinese medicines, chemical drugs, and health supplements. The organization is particularly noted for its specialization in pediatric medicine, marketed under the "Little Sunflower" brand, which includes treatments for respiratory and digestive ailments. Its extensive product portfolio also covers gynecological health and general internal medicine. The group operates several integrated production bases and research institutes, facilitating a comprehensive approach to drug formulation and quality control. By leveraging a robust supply chain and a wide-reaching distribution network, the company provides a diverse range of over-the-counter and prescription solutions aimed at improving family health and wellness.

Recent filings

Filing Released Lang Actions
关于注销全资子公司暨调整参股公司投资主体的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the cancellation (注销) of a wholly-owned subsidiary and adjustment of investment subject in an associated company. It includes details about the subsidiary, reasons for cancellation, and confirms no material impact on financials or operations. The document is relatively short (1327 characters) and does not contain financial statements or detailed financial data. It is an official announcement of a corporate action rather than a financial report or regulatory filing. It does not fit categories like Annual Report, Interim Report, or Earnings Release. It is not a voting result or management change announcement. The content aligns best with a Regulatory Filing (RNS) as a general corporate announcement that does not fit other specific categories.
2024-10-28 Chinese
2024年三季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2024 Third Quarter Report" of 葵花药业集团股份有限公司, indicating it is a quarterly financial report. It contains detailed financial statements including balance sheets, profit and loss statements, and cash flow statements for the third quarter of 2024. The document explicitly states it is a quarterly report and includes comprehensive financial data and analysis for the period. It also mentions that the report is unaudited, which is typical for interim or quarterly reports. The length of the document (over 14,000 characters) and the presence of substantive financial data confirm it is the actual report, not just an announcement or summary. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). 9M 2024
2024-10-28 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolutions passed at the company's fifth board of directors' third meeting, including approval of the third quarter report, appointment of an internal audit officer, and other board decisions. It is a formal disclosure of board meeting outcomes, not the full report itself. The document length is short (1232 characters), and it primarily details board meeting decisions and voting results. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management.
2024-10-28 Chinese
关于使用闲置自有资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company (葵花药业集团股份有限公司) regarding the progress of using idle self-owned funds for cash management. It details the amounts invested, types of financial products purchased, risk control measures, and the impact on the company. The document includes tables of financial products, dates, and expected returns, but it is primarily an update on financing activities rather than a full financial report. It does not contain comprehensive financial statements or detailed financial analysis typical of annual or interim reports. The document is about the company's cash management and investment of idle funds, which fits the category of Capital/Financing Update (CAP). The length is about 5500 characters, which is sufficient for a substantive update rather than a brief notice. Therefore, the best classification is CAP with high confidence.
2024-10-28 Chinese
关于聘任内部审计负责人的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the appointment of an internal audit leader at the company 葵花药业集团股份有限公司. It details the board meeting resolutions and qualifications of the appointed individual. There is no financial data, no report attached or referenced as being published, and no mention of audit results or financial statements. This is a management or board-related announcement about personnel changes in internal audit leadership, which fits best under Board/Management Information (MANG). The document length is short and focused on appointment, not a full audit report or annual report.
2024-10-28 Chinese
关于2022年员工持股计划第二个锁定期届满的提示性公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement regarding the expiration of the second lock-up period and the unlocking of shares under the company's 2022 employee stock ownership plan. It includes specifics about the stock transfer, performance targets, audit confirmation of financial results, individual performance assessments, and subsequent arrangements for the plan. The content focuses on employee stock plans, share unlocking, and related performance criteria rather than financial results, management changes, or regulatory filings. It is not a full financial report, earnings release, or management discussion. It is also not a simple announcement of a report publication but a substantive disclosure about share unlocking and employee stock plan status. Therefore, the document fits best under the category of Capital/Financing Update (CAP), as it relates to changes in capital structure through employee stock ownership plan share unlocking and related disclosures.
2024-10-28 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.